Details of the Drug

General Information of Drug (ID: DMYTE6L)

Drug Name
Enoxacin
Synonyms
Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Approved [1], [2]
Therapeutic Class
Antiinfective Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 320.32
Topological Polar Surface Area (xlogp) -0.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [3]
Bioavailability
The bioavailability of drug is 90% [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 5.4 mL/min/kg [5]
Elimination
45% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 - 6 hours [5]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 62.43637 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.8% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.6 mg/mL [3]
Chemical Identifiers
Formula
C15H17FN4O3
IUPAC Name
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
Canonical SMILES
CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O
InChI
InChI=1S/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)
InChIKey
IDYZIJYBMGIQMJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3229
ChEBI ID
CHEBI:157175
CAS Number
74011-58-8
DrugBank ID
DB00467
TTD ID
D0R8ER
VARIDT ID
DR01280
ACDINA ID
D01048

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [8]
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Enoxacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Tretinoin DM49DUI Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Tretinoin. Acne vulgaris [ED80] [32]
Idarubicin DMM0XGL Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Idarubicin. Acute myeloid leukaemia [2A60] [32]
Daunorubicin DMQUSBT Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Daunorubicin. Acute myeloid leukaemia [2A60] [32]
Magnesium Sulfate DMVEK07 Moderate Decreased absorption of Enoxacin due to formation of complexes caused by Magnesium Sulfate. Acute pain [MG31] [33]
Aminophylline DML2NIB Major Decreased metabolism of Enoxacin caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [34]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Enoxacin caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [35]
Temozolomide DMKECZD Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Temozolomide. Brain cancer [2A00] [32]
Lomustine DMMWSUL Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Lomustine. Brain cancer [2A00] [32]
Thiotepa DMIZKOP Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Thiotepa. Breast cancer [2C60-2C6Y] [32]
Ketoprofen DMRKXPT Moderate Additive CNS depression effects by the combination of Enoxacin and Ketoprofen. Chronic pain [MG30] [36]
Irinotecan DMP6SC2 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Irinotecan. Colorectal cancer [2B91] [32]
Capecitabine DMTS85L Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Capecitabine. Colorectal cancer [2B91] [32]
Mestranol DMG3F94 Moderate Decreased absorption of Enoxacin due to formation of complexes caused by Mestranol. Contraceptive management [QA21] [37]
Mycophenolic acid DMU65NK Moderate Altered absorption of Enoxacin due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [38]
Duloxetine DM9BI7M Major Decreased metabolism of Enoxacin caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [39]
PMID28870136-Compound-49 DMTUC9E Moderate Decreased metabolism of Enoxacin caused by PMID28870136-Compound-49 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [40]
Stiripentol DMMSDOY Moderate Decreased metabolism of Enoxacin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Mefenamic acid DMK7HFI Moderate Additive CNS stimulant effects by the combination of Enoxacin and Mefenamic acid. Female pelvic pain [GA34] [36]
Nizatidine DMGFV3Z Minor Decreased absorption of Enoxacin due to altered gastric pH caused by Nizatidine. Gastro-oesophageal reflux disease [DA22] [41]
Cimetidine DMH61ZB Minor Decreased absorption of Enoxacin due to altered gastric pH caused by Cimetidine. Gastro-oesophageal reflux disease [DA22] [41]
Procarbazine DMIK367 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Procarbazine. Hodgkin lymphoma [2B30] [32]
Didanosine DMI2QPE Moderate Decreased absorption of Enoxacin due to formation of complexes caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [42]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Enoxacin and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [43]
Fludrocortisone DMUDIR8 Major Increased risk of tendinitis/tendon rupture by the combination of Enoxacin and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [44]
Pirfenidone DM6VZFQ Major Decreased metabolism of Enoxacin caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [35]
Meclofenamic acid DM05FXR Moderate Additive CNS stimulant effects by the combination of Enoxacin and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [45]
Ramelteon DM7IW9J Moderate Decreased metabolism of Enoxacin caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [46]
Tasimelteon DMLOQ1V Major Decreased metabolism of Enoxacin caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [47]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Enoxacin and Polyethylene glycol. Irritable bowel syndrome [DD91] [48]
Alosetron DML2A03 Moderate Decreased metabolism of Enoxacin caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [49]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Enoxacin caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [50]
Lurbinectedin DMEFRTZ Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Lurbinectedin. Lung cancer [2C25] [32]
Fludarabine DMVRLT7 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Fludarabine. Malignant haematopoietic neoplasm [2B33] [32]
Pentostatin DM0HXDS Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Pentostatin. Mature B-cell leukaemia [2A82] [32]
Clofarabine DMCVJ86 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Clofarabine. Mature B-cell lymphoma [2A85] [32]
Vincristine DMINOX3 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Vincristine. Mature B-cell lymphoma [2A85] [32]
Mercaptopurine DMTM2IK Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Mercaptopurine. Mature B-cell lymphoma [2A85] [32]
Cytarabine DMZD5QR Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Cytarabine. Mature B-cell lymphoma [2A85] [32]
Mechlorethamine DM0CVXA Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Mechlorethamine. Mature T-cell lymphoma [2A90] [32]
Dacarbazine DMNPZL4 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Dacarbazine. Melanoma [2C30] [32]
Ethinyl estradiol DMODJ40 Moderate Decreased absorption of Enoxacin due to formation of complexes caused by Ethinyl estradiol. Menopausal disorder [GA30] [37]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Enoxacin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [51]
Riluzole DMECBWN Minor Decreased metabolism of Enoxacin caused by Riluzole mediated inhibition of CYP450 enzyme. Motor neuron disease [8B60] [52]
Melphalan DMOLNHF Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Melphalan. Multiple myeloma [2A83] [32]
Deflazacort DMV0RNS Major Increased risk of tendinitis/tendon rupture by the combination of Enoxacin and Deflazacort. Muscular dystrophy [8C70] [44]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Enoxacin and Methoxsalen. Mycosis fungoides [2B01] [53]
Hydroxyurea DMOQVU9 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Hydroxyurea. Myeloproliferative neoplasm [2A20] [32]
Busulfan DMXYJ9C Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Busulfan. Myeloproliferative neoplasm [2A20] [32]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Enoxacin and Bupropion. Nicotine use disorder [6C4A] [54]
Diclofenac DMPIHLS Moderate Additive CNS depression effects by the combination of Enoxacin and Diclofenac. Osteoarthritis [FA00-FA05] [36]
Naproxen DMZ5RGV Moderate Additive CNS stimulant effects by the combination of Enoxacin and Naproxen. Osteoarthritis [FA00-FA05] [36]
Carboplatin DMG281S Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Carboplatin. Ovarian cancer [2C73] [32]
Altretamine DMKLAYG Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Altretamine. Ovarian cancer [2C73] [32]
Topotecan DMP6G8T Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Topotecan. Ovarian cancer [2C73] [32]
Aspirin DM672AH Moderate Additive CNS stimulant effects by the combination of Enoxacin and Aspirin. Pain [MG30-MG3Z] [45]
Etodolac DM6WJO9 Moderate Additive CNS depression effects by the combination of Enoxacin and Etodolac. Pain [MG30-MG3Z] [36]
Diflunisal DM7EN8I Moderate Additive CNS depression effects by the combination of Enoxacin and Diflunisal. Pain [MG30-MG3Z] [36]
Ibuprofen DM8VCBE Moderate Additive CNS depression effects by the combination of Enoxacin and Ibuprofen. Pain [MG30-MG3Z] [36]
Piroxicam DMTK234 Moderate Additive CNS stimulant effects by the combination of Enoxacin and Piroxicam. Pain [MG30-MG3Z] [36]
Rasagiline DM3WKQ4 Major Decreased metabolism of Enoxacin caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [53]
Ranitidine DM0GUSX Minor Decreased absorption of Enoxacin due to altered gastric pH caused by Ranitidine. Peptic ulcer [DA61] [41]
Famotidine DMRL3AB Minor Decreased absorption of Enoxacin due to altered gastric pH caused by Famotidine. Peptic ulcer [DA61] [41]
Prednisone DM2HG4X Major Increased risk of tendinitis/tendon rupture by the combination of Enoxacin and Prednisone. Postoperative inflammation [1A00-CA43] [44]
Choline salicylate DM8P137 Moderate Additive CNS stimulant effects by the combination of Enoxacin and Choline salicylate. Postoperative inflammation [1A00-CA43] [45]
Hydrocortisone DMGEMB7 Major Increased risk of tendinitis/tendon rupture by the combination of Enoxacin and Hydrocortisone. Postoperative inflammation [1A00-CA43] [44]
Salsalate DM13P4C Moderate Additive CNS stimulant effects by the combination of Enoxacin and Salsalate. Rheumatoid arthritis [FA20] [36]
Sulindac DM2QHZU Moderate Additive CNS stimulant effects by the combination of Enoxacin and Sulindac. Rheumatoid arthritis [FA20] [36]
Celecoxib DM6LOQU Moderate Additive CNS depression effects by the combination of Enoxacin and Celecoxib. Rheumatoid arthritis [FA20] [36]
Oxaprozin DM9UB0P Moderate Additive CNS stimulant effects by the combination of Enoxacin and Oxaprozin. Rheumatoid arthritis [FA20] [36]
Flurbiprofen DMGN4BY Moderate Additive CNS depression effects by the combination of Enoxacin and Flurbiprofen. Rheumatoid arthritis [FA20] [36]
Fenoprofen DML5VQ0 Moderate Additive CNS depression effects by the combination of Enoxacin and Fenoprofen. Rheumatoid arthritis [FA20] [36]
Dexamethasone DMMWZET Major Increased risk of tendinitis/tendon rupture by the combination of Enoxacin and Dexamethasone. Rheumatoid arthritis [FA20] [44]
Tolmetin DMWUIJE Moderate Additive CNS stimulant effects by the combination of Enoxacin and Tolmetin. Rheumatoid arthritis [FA20] [36]
Chlorpromazine DMBGZI3 Moderate Decreased metabolism of Enoxacin caused by Chlorpromazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [53]
Asenapine DMSQZE2 Moderate Decreased metabolism of Enoxacin caused by Asenapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [55]
Pimozide DMW83TP Moderate Decreased metabolism of Enoxacin caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [56]
Dactinomycin DM2YGNW Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Dactinomycin. Solid tumour/cancer [2A00-2F9Z] [32]
Methylprednisolone DM4BDON Major Increased risk of tendinitis/tendon rupture by the combination of Enoxacin and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [44]
Cyclophosphamide DM4O2Z7 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Cyclophosphamide. Solid tumour/cancer [2A00-2F9Z] [32]
Vinblastine DM5TVS3 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Vinblastine. Solid tumour/cancer [2A00-2F9Z] [32]
Ifosfamide DMCT3I8 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [32]
Docetaxel DMDI269 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [32]
Mitoxantrone DMM39BF Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [32]
Etoposide DMNH3PG Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Etoposide. Solid tumour/cancer [2A00-2F9Z] [32]
Prednisolone DMQ8FR2 Major Increased risk of tendinitis/tendon rupture by the combination of Enoxacin and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [44]
Cisplatin DMRHGI9 Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Cisplatin. Solid tumour/cancer [2A00-2F9Z] [32]
Fluorouracil DMUM7HZ Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Fluorouracil. Solid tumour/cancer [2A00-2F9Z] [32]
Taxol DMUOT9V Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Taxol. Solid tumour/cancer [2A00-2F9Z] [32]
Doxorubicin DMVP5YE Minor Decreased absorption of Enoxacin due to intestinal mucosa variation caused by Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [32]
Tizanidine DMR2IQ4 Major Decreased metabolism of Enoxacin caused by Tizanidine mediated inhibition of CYP450 enzyme. Tonus and reflex abnormality [MB47] [57]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Enoxacin due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [38]
Triamcinolone DM98IXF Major Increased risk of tendinitis/tendon rupture by the combination of Enoxacin and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [44]
⏷ Show the Full List of 92 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Benzoic acid E00009 243 Antimicrobial preservative
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Stearyl alcohol E00172 8221 Emollient; Emulsifying agent; Stiffening agent; Viscosity-controlling agent
Water E00035 962 Solvent
Octyldodecanol E00269 21414 Emollient; Emulsifying agent; Lubricant; Solvent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Enoxacin 1% cream 1% Cream Topical
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019616.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 BDDCS applied to over 900 drugs
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
8 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
9 Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther. 2009 Feb;328(2):628-34.
10 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
11 Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
12 Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
13 Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
14 Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
15 FDA Drug Development and Drug Interactions
16 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
17 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
18 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
19 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
20 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
21 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
22 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
23 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
24 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
25 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
26 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
27 Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
28 Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
29 Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
30 Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
31 Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.
32 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
33 Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
34 Beckmann J, Elsaber W, Gundert-Remy U, Hertrampf R "Enoxacin: a potent inhibitor of theophylline metabolism." Eur J Clin Pharmacol 33 (1987): 227-30. [PMID: 3480222]
35 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
36 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
37 Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
38 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
39 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
40 Magnusson M, Bergstrand IC, Bjorkman S, Heijl A, Roth B, Hoglund P "A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans." Br J Clin Pharmacol 61 (2006): 138-47. [PMID: 16433868]
41 Lebsack ME, Nix D, Ryerson B, et al "Effect of gastric acidity on enoxacin absorption." Clin Pharmacol Ther 52 (1992): 252-6. [PMID: 1526081]
42 Deppermann KM, Lode H "Fluoroquinolones: interaction profile during enteral absorption." Drugs 45 Suppl 3 (1993): 65-72. [PMID: 7689454]
43 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
44 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
45 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
46 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
47 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
48 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
49 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
50 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
51 Canadian Pharmacists Association.
52 Product Information. Rilutek (riluzole). Rhone-Poulenc Rorer, Collegeville, PA.
53 Cerner Multum, Inc. "Australian Product Information.".
54 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
55 Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
56 Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ "Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication." Am J Med Sci 309 (1995): 315-6. [PMID: 7771501]
57 Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]